

Product datasheet for **TL314772V**

Annexin A2 (ANXA2) Human shRNA Lentiviral Particle (Locus ID 302)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Annexin A2 (ANXA2) Human shRNA Lentiviral Particle (Locus ID 302)
Locus ID:	302
Synonyms:	ANX2; ANX2L4; CAL1H; HEL-S-270; LIP2; LPC2; LPC2D; P36; PAP-IV
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ANXA2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001002857 , NM_001002858 , NM_001136015 , NM_004039 , NM_004039.1 , NM_004039.2 , NM_001002858.1 , NM_001002858.2 , NM_001136015.1 , NM_001136015.2 , BC016774 , BC016774.1 , BC023990 , BC023990.1 , BC093056 , BC001388 , BC001748 , BC009564 , BC013843 , BC015834 , BC021114 , BC052558 , BC052567 , BC066955 , BC068065 , NM_004039.3 , NM_001136015.3
UniProt ID:	P07355
Summary:	This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. This protein functions as an autocrine factor which heightens osteoclast formation and bone resorption. This gene has three pseudogenes located on chromosomes 4, 9 and 10, respectively. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. Annexin A2 expression has been found to correlate with resistance to treatment against various cancer forms. [provided by RefSeq, Dec 2019]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).